Arixtra (fondaparinux sodium) October 2008
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- October 2008
|The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.|
Summary of Changes to Contraindications and Warnings
...Isolated cases of elevated aPTT temporally associated with bleeding events have been reported following administration of Arixtra (with or without concomitant administration of other anticoagulants) (see ADVERSE REACTIONS: Postmarketing Experience).
...In post-marketing experience, isolated occurrences of aPTT elevations have been reported following administration of -Arixtra (see PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS: Postmarketing Experience).
...Isolated occurrences of thrombocytopenia with thrombosis that manifested similar to heparin induced thrombocytopenia have been reported with use of Arixtra in postmarketing experience (see ADVERSE REACTIONS: Postmarketing Experience)...
Label approved 10/17/2008 is not available on this site